Aerie Pharmaceuticals Inc. (AERI) plunged more than 65% in after-hours on Thursday as its first phase 3 registration trial of glaucoma treatment, Rhopressa, dubbed Rocket-1, failed to meet the primary endpoint.
Forex – financial instrument.Forex news
Aerie Pharmaceuticals Inc. (AERI) plunged more than 65% in after-hours on Thursday as its first phase 3 registration trial of glaucoma treatment, Rhopressa, dubbed Rocket-1, failed to meet the primary endpoint.